Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23508209 | 0.87 | CDK2 (0.38) | GSK3BCDK2 | |
| SCHEMBL23508046 | 0.84 | GSK3B (0.37) | GSK3BCDK2 | |
| SCHEMBL23508061 | 0.83 | GSK3B (0.38) | GSK3BCDK2 | |
| SCHEMBL23508105 | 0.80 | CDK2 (0.36) | GSK3BCDK2 | |
| SCHEMBL23508254 | 0.79 | CDK12 (0.40) | CDK2 | |
| SCHEMBL23497710 | 0.79 | EGLN1 (0.36) | GSK3BCDK2 | |
| SCHEMBL23508266 | 0.79 | CSNK1E (0.40) | GSK3B | |
| SCHEMBL23497830 | 0.78 | HSD17B10 (0.46) | — | |
| SCHEMBL23508238 | 0.77 | PDE10A (0.43) | GSK3BCDK2 | |
| SCHEMBL30012211 | 0.76 | CACNA1H (0.34) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117034-A1 | PYRAZOLOTRIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-20 | — | — | US | disclosed |
| US-20230117034-A1 | PYRAZOLOTRIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-20 | — | — | US | disclosed |
| EP-4073072-A1 | PYRAZOLOTRIAZINES | Bayer Aktiengesellschaft (DE) | 2022-10-19 | — | — | EP | disclosed |
| CN-115023427-A | Pyrazolotriazines | 拜耳公司 | 2022-09-06 | — | — | CN | disclosed |
| WO-2021116178-A1 | PYRAZOLOTRIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021116178-A1 | PYRAZOLOTRIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117034-A1 | PYRAZOLOTRIAZINES | BRCA1, TPX2, CCND2 | GSK3B 3545/4885CDK2 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.